TapewireFind a company

person · Reporting owner

Stokes Frank

Disclosed activity across 2 companies

Tapewire entity
22194
SEC CIK
0001782815

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CASTLE BIOSCIENCES INCCSTL · Entity 359Chief Financial OfficerAugust 14, 2026August 18, 2026
EXAGEN INC.XGN · Entity 935DirectorJune 09, 2026June 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CASTLE BIOSCIENCES INC

Report date August 14, 2026 · Filed August 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect35,177 Reported balance After 2026-08-14 transaction · row 1
1 source row

Row 1 · 2026-08-14 · Sale · Disposed 24,908 · Balance 35,177

F1: This transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

EXAGEN INC.

Report date June 09, 2026 · Filed June 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2036-06-08Direct112,500 Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-09 · Grant · Acquired 37,500 · Balance 112,500

F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 03, 2020 Filed Dec 4, 2020 21:13 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 2,000 $0.00 Strike: $3.38 $0.00
Disclosure

SEC source: 0001447362-20-000272 · wf-form4_160711641161876.xml · derivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,712

Underlying: Common Stock · 2,000 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the 28,712 shares originally subject to the option vested on March 13, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Read SEC document
December 03, 2020 Filed Dec 4, 2020 21:13 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 2,000 $3.38 $6,760.00
Disclosure

SEC source: 0001447362-20-000272 · wf-form4_160711641161876.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,886

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 13, 2020 Filed Nov 16, 2020 21:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 13,000 $0.00 Strike: $2.39 $0.00
Disclosure

SEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · derivative · entry 11

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,137

Underlying: Common Stock · 13,000 shares

Expires 2028-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F8 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
November 13, 2020 Filed Nov 16, 2020 21:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 200 $52.04 $10,408.00
Disclosure

SEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 9

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,886

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F7 · price: This transaction was executed in multiple trades at prices ranging from $52.010 to $52.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
November 13, 2020 Filed Nov 16, 2020 21:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 633 $51.30 $32,474.17
Disclosure

SEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 8

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,086

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F6 · price: This transaction was executed in multiple trades at prices ranging from $51.000 to $51.800, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
November 13, 2020 Filed Nov 16, 2020 21:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 12,167 $50.41 $613,301.97
Disclosure

SEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 7

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,719

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F5 · price: This transaction was executed in multiple trades at prices ranging from $50.000 to $50.885, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
November 13, 2020 Filed Nov 16, 2020 21:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 13,000 $2.39 $31,070.00
Disclosure

SEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 6

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,886

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

Read SEC document
November 12, 2020 Filed Nov 16, 2020 21:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 13,000 $0.00 Strike: $2.39 $0.00
Disclosure

SEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · derivative · entry 10

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,137

Underlying: Common Stock · 13,000 shares

Expires 2028-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F8 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
November 12, 2020 Filed Nov 16, 2020 21:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 69 $52.96 $3,654.24
Disclosure

SEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 5

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,886

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

Read SEC document
November 12, 2020 Filed Nov 16, 2020 21:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 5,731 $52.20 $299,163.93
Disclosure

SEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 4

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,955

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F4 · price: This transaction was executed in multiple trades at prices ranging from $51.770 to $52.675, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
November 12, 2020 Filed Nov 16, 2020 21:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 2,121 $51.19 $108,573.99
Disclosure

SEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 3

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,686

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F3 · price: This transaction was executed in multiple trades at prices ranging from $50.630 to $51.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
November 12, 2020 Filed Nov 16, 2020 21:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 5,079 $50.20 $254,970.88
Disclosure

SEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,807

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $49.585 to $50.560, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
November 12, 2020 Filed Nov 16, 2020 21:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 13,000 $2.39 $31,070.00
Disclosure

SEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,886

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

Read SEC document
October 14, 2020 Filed Oct 15, 2020 20:20 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 13,000 $0.00 Strike: $2.39 $0.00
Disclosure

SEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · derivative · entry 8

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,137

Underlying: Common Stock · 13,000 shares

Expires 2028-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F6 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
October 14, 2020 Filed Oct 15, 2020 20:20 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 1,300 $55.13 $71,674.20
Disclosure

SEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 6

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,886

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F5 · price: This transaction was executed in multiple trades at prices ranging from $55.115 to $55.140, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
October 14, 2020 Filed Oct 15, 2020 20:20 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 8,300 $54.58 $453,014.00
Disclosure

SEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 5

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,186

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F4 · price: This transaction was executed in multiple trades at prices ranging from $54.105 to $55.100, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
October 14, 2020 Filed Oct 15, 2020 20:20 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 3,400 $53.06 $180,417.60
Disclosure

SEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 4

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,486

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F3 · price: This transaction was executed in multiple trades at prices ranging from $52.810 to $53.780, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
October 14, 2020 Filed Oct 15, 2020 20:20 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 13,000 $2.39 $31,070.00
Disclosure

SEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 3

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,886

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

Read SEC document
October 13, 2020 Filed Oct 15, 2020 20:20 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 13,000 $0.00 Strike: $2.39 $0.00
Disclosure

SEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · derivative · entry 7

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,137

Underlying: Common Stock · 13,000 shares

Expires 2028-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F6 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
October 13, 2020 Filed Oct 15, 2020 20:20 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 13,000 $54.79 $712,283.00
Disclosure

SEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,886

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $54.280 to $55.200, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
October 13, 2020 Filed Oct 15, 2020 20:20 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 13,000 $2.39 $31,070.00
Disclosure

SEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,886

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

Read SEC document
September 15, 2020 Filed Sep 16, 2020 20:05 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 13,000 $0.00 Strike: $2.39 $0.00
Disclosure

SEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · derivative · entry 7

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,137

Underlying: Common Stock · 13,000 shares

Expires 2028-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F6 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
September 15, 2020 Filed Sep 16, 2020 20:05 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 7,741 $49.43 $382,606.67
Disclosure

SEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 5

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,886

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F5 · price: This transaction was executed in multiple trades at prices ranging from $49.160 to $50.000, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
September 15, 2020 Filed Sep 16, 2020 20:05 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 5,259 $48.52 $255,145.64
Disclosure

SEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 4

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,627

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F4 · price: This transaction was executed in multiple trades at prices ranging from $48.145 to $49.120, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
September 15, 2020 Filed Sep 16, 2020 20:05 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 13,000 $2.39 $31,070.00
Disclosure

SEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 3

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,886

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:05 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 13,000 $0.00 Strike: $2.39 $0.00
Disclosure

SEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · derivative · entry 6

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,137

Underlying: Common Stock · 13,000 shares

Expires 2028-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F6 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:05 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 13,000 $49.98 $649,779.00
Disclosure

SEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,886

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F3 · price: This transaction was executed in multiple trades at prices ranging from $49.410 to $50.170, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:05 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 13,000 $2.39 $31,070.00
Disclosure

SEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,886

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F2 · balance_after: Includes 826 shares and 1,060 shares acquired on February 28, 2020 and August 31, 2020, respectively, under the Issuer's employee stock purchase plan.

Read SEC document
December 13, 2019 Filed Dec 17, 2019 21:13 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 GrantStock option (right to buy) · Derivative 55,000 $0.00 Strike: $29.50 $0.00
Disclosure

SEC source: 0001447362-19-000026 · wf-form4_157661719990981.xml · derivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2020-12-12

F1 · derivative.exercise_date: 25% of the shares shall vest on December 13, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.